Search - tctmd.com

Displaying 1 - 7 of 7

Sort: Relevancy | Date

Presentation THT 2025

Tafamidis Impact on Incidence of Pacemaker and ICD Placement in ATTR-CM Patients

Presenter: Justin Pawloski

February 12, 2025

Presentation THT Abstracts 2025

Tafamidis Impact on Incidence of Pacemaker and ICD Placement in ATTR-CM Patients

Presenter: Justin Pawloski

February 11, 2025

Presentation THT Abstracts 2025

Determining Equity and Timeliness of ATTR-CM Diagnosis

Presenter: Anubodh Varshney

February 11, 2025

Presentation THT 2025

Determining Equity and Timeliness of ATTR-CM Diagnosis

Presenter: Anubodh Varshney

February 11, 2025

Presentation ACC 2024

Acoramidis May Improve Cardiac Function and Promote Regression in Transthyretin Amyloid Cardiomyopathy: Data From the ATTRibute-CM Cardiac Magnetic Resonance Substudy

Presenter: Yousuf Razvi

April 06, 2024

Presentation THT 2023

ATTR-CM is a serious and underrecognized cause of heart failure. This program will help raise awareness of the signs and symptoms of ATTR-CM, the role of cardiac health professionals in diagnosis, and a treatment option for patients with ATTR-CM

Presenter: Charles Dow

March 20, 2023

Presentation THT 2022

Transthyretin Amyloid Cardiomyopathy (ATTR-CM): Evaluating clinical findings to support earlier diagnosis and management

Presenter: Gregg Lanier

February 01, 2022

Advertisement

Tafamidis Impact on Incidence of Pacemaker and ICD Placement in ATTR-CM Patients

Tafamidis Impact on Incidence of Pacemaker and ICD Placement in ATTR-CM Patients

Determining Equity and Timeliness of ATTR-CM Diagnosis

Determining Equity and Timeliness of ATTR-CM Diagnosis

Acoramidis May Improve Cardiac Function and Promote Regression in Transthyretin Amyloid Cardiomyopathy: Data From the ATTRibute-CM Cardiac Magnetic Resonance Substudy

ATTR-CM is a serious and underrecognized cause of heart failure. This program will help raise awareness of the signs and symptoms of ATTR-CM, the role of cardiac health professionals in diagnosis, and a treatment option for patients with ATTR-CM

Transthyretin Amyloid Cardiomyopathy (ATTR-CM): Evaluating clinical findings to support earlier diagnosis and management

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content